Results 121 to 130 of about 1,268 (176)

Case Report: Use of telitacicept for ocular myasthenia gravis. [PDF]

Front Immunol
Yang A, Zhao J, Li F, Pang R, Zang W.
europepmc   +1 more source

Efgartigimod as an Add-on Therapy for Anti-IgLON5 Disease: A Case Report. [PDF]

Neurol Ther
Wang Z, Huang ZY, Liu L, Zhang YX, Zhang XY.   +4 more
europepmc   +1 more source

Real-world use of efgartigimod in acetylcholine receptor antibody-positive generalized myasthenia gravis: experience from two centers in Greece and Cyprus. [PDF]

Front Neurol
Tsokkos T, Strataki E, Tzavella D, Zamba-Papanicolaou E, Kleopa KA, Zouvelou V.   +5 more
europepmc   +1 more source

Heterogeneous response to efgartigimod in real-world experience with myasthenia gravis: Predictors and treatment strategies. [PDF]

Neurotherapeutics
Fuchs L, Vigiser I, Kolb H, Regev K, Drory VE, Dori A, Magalashvili D, Caller T, Kenan G, Mechnik Steen Y, Hellmann M, Wilf-Yarkoni A, Friedman Korn T, Vaknin-Dembinsky A, Bsoul A, Shelly S, Karni A.   +16 more
europepmc   +1 more source

Real-World Outcomes of Efgartigimod in Adult Myasthenia Gravis. [PDF]

Cureus
Krall T, Byrne S, Kelbert J, Chrisman C.
europepmc   +1 more source

A Prospective Clinical Trial of Efgartigimod for New-Onset Generalized Myasthenia Gravis. [PDF]

Curr Neuropharmacol
Ma C, Shen J, Zhu Y, Zhu R.
europepmc   +1 more source

Efficacy, Safety, and Tolerability of Subcutaneous Efgartigimod PH20 in Chinese Patients With Chronic Inflammatory Demyelinating Polyneuropathy: A Prespecified Subpopulation Analysis of the Multicentre, Randomised-Withdrawal, Double-Blind, Placebo-Controlled, Phase II ADHERE Trial. [PDF]

J Clin Neurol
Lin J, Ding M, Wang Q, Chang T, Zhao Y, Da Y, Tan S, Hong D, Jiang H, Zou Z, Yang H, Bu B, Liang H, Wang Y, Guo A, He D, Wang Y, Ding J, Guo J, Shi J, Zhang Y, Liu J, Liu J, Chen L, Wu J, Shao J, Hofman E, Hoorick BV, Mole T, Li W, Lu Z.   +30 more
europepmc   +1 more source

Efficacy and safety of efgartigimod PH20 SC for Sjögren's disease-associated dryness: study protocol for an investigator-initiated, multicenter, phase 2, randomized, double-blind, placebo-controlled trial (OASIS study). [PDF]

Front Med (Lausanne)
Endo Y, Hosogaya N, Fukushige Y, Narita S, Jacobs J, Reiss W, Imai Y, Shimizu T, Koga T, Yamamoto H, Sakai T, Takagi Y, Sumi M, Kawakami A.   +13 more
europepmc   +1 more source

Efgartigimod for Generalized Myasthenia Gravis and Beyond: A Narrative Review of Its Pharmacological Profile, Clinical Utility, and Expanding Applications. [PDF]

Biomedicines
Mansour GK, Alangari L, Khosyfan L, Alhammad R, Hajjar AW.   +4 more
europepmc   +1 more source

Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach. [PDF]

Muscle Nerve
Hoffmann S, Zhao S, Callewaert F, Schoppe S, Rózsa C, Spillane J.   +5 more
europepmc   +1 more source